Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
257M
-
Number of holders
-
706
-
Total 13F shares, excl. options
-
246M
-
Shares change
-
+3.75M
-
Total reported value, excl. options
-
$45B
-
Value change
-
+$698M
-
Put/Call ratio
-
0.84
-
Number of buys
-
341
-
Number of sells
-
-324
-
Price
-
$183.38
Significant Holders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) as of Q2 2019
833 filings reported holding VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock as of Q2 2019.
VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) has 706 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 246M shares
of 257M outstanding shares and own 95.77% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (24.9M shares), FMR LLC (24.7M shares), BlackRock Inc. (20.7M shares), VANGUARD GROUP INC (19.7M shares), Capital World Investors (11.4M shares), STATE STREET CORP (11.4M shares), WELLINGTON MANAGEMENT GROUP LLP (8.26M shares), JENNISON ASSOCIATES LLC (6.34M shares), RENAISSANCE TECHNOLOGIES LLC (5.56M shares), and Clearbridge Investments, LLC (5.18M shares).
This table shows the top 706 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.